GeoVax Labs’ (GOVX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a report issued on Friday,Benzinga reports. The firm currently has a $8.00 price target on the stock.

Several other equities analysts have also commented on GOVX. Noble Financial raised their price target on GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a research note on Monday, August 19th. Alliance Global Partners assumed coverage on shares of GeoVax Labs in a research report on Monday, November 11th. They set a “buy” rating and a $15.00 target price on the stock. Finally, EF Hutton Acquisition Co. I raised shares of GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 23rd. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GeoVax Labs currently has a consensus rating of “Buy” and a consensus price target of $13.25.

GeoVax Labs Stock Performance

Shares of NASDAQ:GOVX opened at $3.03 on Friday. The business has a 50 day simple moving average of $2.36 and a two-hundred day simple moving average of $2.63. GeoVax Labs has a 1 year low of $1.09 and a 1 year high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.29) by $0.38. The company had revenue of $2.79 million during the quarter, compared to analysts’ expectations of $1.84 million. During the same period in the prior year, the business earned ($4.80) EPS. As a group, equities research analysts predict that GeoVax Labs will post -4.49 EPS for the current fiscal year.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.